Quinone derivatives isolated from the endolichenic fungus Phialocephala fortinii are Mdr1 modulators that combat azole resistance in Candida albicans

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Xie, Fei ^a   Chang, Wenqiang ^a   Zhang, Ming ^a   Li, Ying ^a   Li, Wei ^a   Shi, Hongzhuo ^a   Zheng, Sha ^a   Lou, Hongxiang ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; BENZOQUINONE DERIVATIVE; BIOLOGICAL PRODUCT; MULTIDRUG RESISTANCE PROTEIN 1; PYRROLE DERIVATIVE; QUINONE DERIVATIVE;

ANTIFUNGAL RESISTANCE; ASCOMYCETES; CANDIDA ALBICANS; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; HIGH THROUGHPUT SCREENING; HUMAN; IC50; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; PHYSIOLOGY; PRECLINICAL STUDY;

ANTIFUNGAL AGENTS; ASCOMYCOTA; ATP-BINDING CASSETTE, SUB-FAMILY B, MEMBER 1; AZOLES; BENZOQUINONES; BIOLOGICAL PRODUCTS; CANDIDA ALBICANS; CELL SURVIVAL; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, FUNGAL; DRUG RESISTANCE, MULTIPLE; DRUG SYNERGISM; GENE EXPRESSION REGULATION; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE;

EID: 84988651966     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep33687     Document Type: Article

References (55)

1. Goodman, J. L. et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N. Engl. J. Med. 326, 845-851 (1992).
2. US Public Health Service, Infectious Diseases Society of America, & Prevention of Opportunistic Infections Working Group. 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Infect Dis Obstet Gynecol 10, 3 (2002).
3. Ascioglu, S. et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin. Infect. Dis. 34, 7-14 (2002).
4. Kontoyiannis, D. P. & Lewis, R. E. Antifungal drug resistance of pathogenic fungi. Lancet 359, 1135-1144 (2002).
5. Pfaller, M. A. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am. J. Med. 125, S3-S13 (2012).
6. Arendrup, M. Update on antifungal resistance in Aspergillus and Candida. Clin. Microbiol. Infect. 20, 42-48 (2014).
7. Kanafani, Z. A. & Perfect, J. R. Resistance to antifungal agents: mechanisms and clinical impact. Clin. Infect. Dis. 46, 120-128 (2008).
8. Spampinato, C. & Leonardi, D. Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents. Biomed Res Int 2013 (2013).
9. Sanglard, D. & Odds, F. C. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2, 73-85 (2002).
10. Cannon, R. et al. Efflux-mediated antifungal drug resistance. Clin. Microbiol. Rev. 22, 291-321 (2009).
11. Albertson, G. D., Niimi, M., Cannon, R. D. & Jenkinson, H. F. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob. Agents Chemother. 40, 2835-2841 (1996).
12. Sanglard, D. et al. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob. Agents Chemother. 39, 2378-2386 (1995).
13. White, T. C. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 41, 1482-1487 (1997).
14. Lopez-Ribot, J. L. et al. Distinct Patterns of Gene Expression Associated with Development of Fluconazole Resistance in Serial Candida albicans Isolates from Human Immunodeficiency Virus-Infected Patients with Oropharyngeal Candidiasis. Antimicrob. Agents Chemother. 42, 2932-2937 (1998).
15. Perea, S. et al. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 45, 2676-2684 (2001).
16. Wirsching, S., Michel, S. & Morschhauser, J. Targeted gene disruption in Candida albicans wild-type strains: the role of the MDR1 gene in fluconazole resistance of clinical Candida albicans isolates. Mol. Microbiol. 36, 856-865 (2000).
17. Liu, S. et al. Combination of fluconazole with non-antifungal agents: a promising approach to cope with resistant Candida albicans infections and insight into new antifungal agent discovery. Int. J. Antimicrob. Agents 43, 395-402 (2014).
18. Monk, B. C. & Goffeau, A. Outwitting multidrug resistance to antifungals. Science 321, 367-369 (2008).
19. Spitzer, M. et al. Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole. Mol. Syst. Biol. 7, 499 (2011).
20. Schuetzer-Muehlbauer, M., Willinger, B., Egner, R., Ecker, G. & Kuchler, K. Reversal of antifungal resistance mediated by ABC efflux pumps from Candida albicans functionally expressed in yeast. Int. J. Antimicrob. Agents 22, 291-300 (2003).
21. Holmes, A. R. et al. The monoamine oxidase a inhibitor clorgyline is a broad-spectrum inhibitor of fungal ABC and MFS transporter efflux pump activities which reverses the azole resistance of Candida albicans and Candida glabrata clinical isolates. Antimicrob. Agents Chemother. 56, 1508-1515 (2012).
22. Harvey, A. L. Natural products in drug discovery. Drug Discov. Today 13, 894-901 (2008).
23. Paterson, I. & Anderson, E. A. The renaissance of natural products as drug candidates. Science 310, 451 (2005).
24. Koehn, F. E. & Carter, G. T. The evolving role of natural products in drug discovery. Nat Rev Drug Discov 4, 206-220 (2005).
25. Zhang, L. et al. Bisbibenzyls, a new type of antifungal agent, inhibit morphogenesis switch and biofilm formation through upregulation of DPP3 in Candida albicans. PloS ONE 6, e28953 (2011).
26. Chang, W., Li, Y., Zhang, L., Cheng, A. & Lou, H. Retigeric acid B attenuates the virulence of Candida albicans via inhibiting adenylyl cyclase activity targeted by enhanced farnesol production. PloS ONE 7, e41624 (2012).
27. Chang, W. et al. Lichen endophyte derived pyridoxatin inactivates Candida growth by interfering with ergosterol biosynthesis. BBAGeneral Subjects 1850, 1762-1771 (2015).
28. Li, Y. et al. Diorcinol D Exerts Fungicidal Action against Candida albicans through Cytoplasm Membrane Destruction and ROS Accumulation. PloS ONE 10, e0128693 (2015).
29. Sakemi, S. et al. CJ-12,371 and CJ-12,372, two novel DNA gyrase inhibitors. Fermentation, isolation, structural elucidation and biological activities. J. Antibiot. 48, 134-142 (1995).
30. Kokubun, T., Veitch, N. C., Bridge, P. D. & Simmonds, M. S. Dihydroisocoumarins and a tetralone from Cytospora eucalypticola. Phytochemistry 62, 779-782 (2003).
31. Zhu, Y. et al. Screening and isolation of antinematodal metabolites against Bursaphelenchus xylophilus produced by fungi. Ann. Microbiol. 58, 375-380 (2008).
32. Holmes, A. R. et al. ABC transporter Cdr1p contributes more than Cdr2p does to fluconazole efflux in fluconazole-resistant Candida albicans clinical isolates. Antimicrob. Agents Chemother. 52, 3851-3862 (2008).
33. Chen, L. et al. Overexpression of CDR1 and CDR2 genes plays an important role in fluconazole resistance in Candida albicans with G487T and T916C mutations. J. Int. Med. Res. 38, 536-545 (2010).
34. Dunkel, N., Blaß, J., Rogers, P. D. & Morschhauser, J. Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains. Mol. Microbiol. 69, 827-840 (2008).
35. Newman, D. J., Cragg, G. M. & Snader, K. M. Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod. 66, 1022-1037 (2003).
36. Arif, T. et al. Natural products-antifungal agents derived from plants. J Asian Nat Prod Res 11, 621-638 (2009).
37. Newman, D. J. & Cragg, G. M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 75, 311-335 (2012).
38. Cragg, G. M. & Newman, D. J. Natural products: a continuing source of novel drug leads. BBA-General Subjects 1830, 3670-3695 (2013).
39. Schubert, S. et al. Regulation of efflux pump expression and drug resistance by the transcription factors Mrr1, Upc2, and Cap1 in Candida albicans. Antimicrob. Agents Chemother. 55, 2212-2223 (2011).
40. Morschhauser, J. et al. The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog 3, e164 (2007).
41. Schubert, S., Popp, C., Rogers, P. D. & Morschhauser, J. Functional dissection of a Candida albicans zinc cluster transcription factor, the multidrug resistance regulator Mrr1. Eukaryotic Cell 10, 1110-1121 (2011).
42. Mogavero, S., Tavanti, A., Senesi, S., Rogers, P. D. & Morschhauser, J. Differential requirement of the transcription factor Mcm1 for activation of the Candida albicans multidrug efflux pump MDR1 by its regulators Mrr1 and Cap1. Antimicrob. Agents Chemother. 55, 2061-2066 (2011).
43. Wu, C.-P., Ohnuma, S. &Ambudkar, S. V. Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol 12, 609 (2011).
44. Thomas, H. & Coley, H. M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer control 10, 159-159 (2003).
45. Takara, K., Sakaeda, T. & Okumura, K. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr. Pharm. Des. 12, 273-286 (2006).
46. Huang, M., Jin, J., Sun, H. & Liu, G. T. Reversal of P-glycoprotein-mediated multidrug resistance of cancer cells by five schizandrins isolated from the Chinese herb Fructus Schizandrae. Cancer. Chemoth. Pharm. 62, 1015-1026 (2008).
47. Wu, C.-Y. et al. PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway. Mol. Cell. Biochem. 359, 347-358 (2012).
48. Soria, J.-C. et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin. Cancer Res. 8, 1178-1184 (2002).
49. Fernandez-Martinez, A. B. et al. Vasoactive intestinal peptide (VIP) induces malignant transformation of the human prostate epithelial cell line RWPE-1. Cancer Lett. 299, 11-21 (2010).
50. Zhang, L. et al. High-throughput synergy screening identifies microbial metabolites as combination agents for the treatment of fungal infections. Proc. Natl. Acad. Sci. USA 104, 4606-4611 (2007).
51. Marchetti, O., Moreillon, P., Glauser, M. P., Bille, J. & Sanglard, D. Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans. Antimicrob. Agents Chemother. 44, 2373-2381 (2000).
52. Clinical and Laboratory Standards Institute, Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, CLSI document M27-A33rd ed., CLSI, Wayne, PA (2008).
53. Spitzer, M. S. et al. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol 90, 1316-1321 (2006).
54. Li, Y. et al. Synergistic and drug-resistant reversing effects of diorcinol D combined with fluconazole against Candida albicans. FEMS Yeast Res. 15 (2015).
55. Chang, W. et al. Retigeric acid B enhances the efficacy of azoles combatinw the virulence and biofilm formqtion of Candida albicans. Biol.0Pharm. Bull. 35, 1794-1801 (2012).